Prothena Corporation plc
PRTA
Market Cap$1.33B
Close$
$35.32
59.7% upside
Current Fair Value
59.7% upsideUndervalued by 59.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.33 Billion |
|---|---|
| Enterprise Value | $789.02 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-3.22 |
| Beta | 1.48 |
| Outstanding Shares | 53,771,845 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.73 |
|---|---|
| PEG | 3.47 |
| Price to Sales | 5.53 |
| Price to Book Ratio | 2.21 |
| Enterprise Value to Revenue | 3.63 |
| Enterprise Value to EBIT | -9.13 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Prothena Corporation plc
7 employees
CEO: Gene Kinney Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and r...